Device type · SET
Immunoassay Blood Test For Amyloid Pathology Assessment
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
SET
Immunology
Device class
Class II
FDA decisions since 2015
4
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Immunoassay Blood Test For Amyloid Pathology Assessment
- Product code
- SET
- Device class
- Class II
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5840
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for SET
Latest FDA decisions
- PrecivityAD2 Test510(k)
K253240 · Decided Aug 19, 2026 · 324 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
K261686 · Decided Aug 19, 2026 · 90 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
- Elecsys Phospho-Tau (181P) PlasmaBreakthrough510(k)
K252163 · Decided Oct 8, 2025 · 90 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioBreakthrough510(k)
K242706 · Decided May 16, 2025 · 249 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1301-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
Z-1302-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
Z-1303-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
Z-1304-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
Z-1305-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
Z-1306-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
Z-1307-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.